DK1848813T3 - Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler - Google Patents
Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-cellerInfo
- Publication number
- DK1848813T3 DK1848813T3 DK06733921.8T DK06733921T DK1848813T3 DK 1848813 T3 DK1848813 T3 DK 1848813T3 DK 06733921 T DK06733921 T DK 06733921T DK 1848813 T3 DK1848813 T3 DK 1848813T3
- Authority
- DK
- Denmark
- Prior art keywords
- cd1d
- activation
- nkt cells
- restricted nkt
- bacterial glycolipid
- Prior art date
Links
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title 1
- 229930186217 Glycolipid Natural products 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 title 1
- 210000000581 natural killer T-cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64815305P | 2005-01-28 | 2005-01-28 | |
| PCT/US2006/002781 WO2006083671A2 (en) | 2005-01-28 | 2006-01-26 | Bacterial glycolipid activation of cd1d-restricted nkt cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1848813T3 true DK1848813T3 (da) | 2013-07-15 |
Family
ID=36777772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06733921.8T DK1848813T3 (da) | 2005-01-28 | 2006-01-26 | Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9295722B2 (enExample) |
| EP (1) | EP1848813B1 (enExample) |
| JP (1) | JP5053101B2 (enExample) |
| AU (1) | AU2006211485B2 (enExample) |
| BR (1) | BRPI0607299A2 (enExample) |
| CA (1) | CA2593715C (enExample) |
| DK (1) | DK1848813T3 (enExample) |
| ES (1) | ES2423005T3 (enExample) |
| PL (1) | PL1848813T3 (enExample) |
| PT (1) | PT1848813E (enExample) |
| WO (1) | WO2006083671A2 (enExample) |
| ZA (1) | ZA200706208B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| WO2007118234A2 (en) | 2006-04-07 | 2007-10-18 | The Scripps Research Institute | Modified -galactosyl ceramides for staining and stimulating natural killer t cells |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
| WO2008128207A1 (en) * | 2007-04-13 | 2008-10-23 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
| US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| AU2013202865B2 (en) * | 2007-11-07 | 2015-03-19 | Abivax | Increase of immune response and targeting by antigens and/or drug linkage |
| EP2058011A1 (en) * | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| EP2060252A1 (en) | 2007-11-19 | 2009-05-20 | Wittycell | New formulation of galactosylceramide derivatives |
| BRPI0820960B8 (pt) * | 2007-12-05 | 2021-05-25 | Abivax | composição, composição farmacêutica, e uso da composição |
| US9220767B2 (en) | 2008-10-08 | 2015-12-29 | Abivax | Vaccine composition for use against influenza |
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| JP6548579B2 (ja) * | 2012-12-06 | 2019-07-24 | ヴィクトリア リンク リミテッド | コンジュゲート化合物 |
| US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
| CN115666586A (zh) * | 2020-04-23 | 2023-01-31 | 加州大学评议会 | 通过激活iNKT细胞清除衰老细胞 |
| KR20230119224A (ko) * | 2020-12-18 | 2023-08-16 | 로레알 | 스핑고모나스 속 박테리아 추출물 |
| FR3117776B1 (fr) * | 2020-12-18 | 2024-03-08 | Oreal | Extrait de bactérie du genreSphingomonas |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
| WO2024107463A1 (en) * | 2022-11-14 | 2024-05-23 | The Trustees Of Columbia University In The City Of New York | 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| ATE191916T1 (de) | 1992-10-22 | 2000-05-15 | Kirin Brewery | Neues sphingolglycolipid und verwendung davon |
| US5780441A (en) | 1993-04-15 | 1998-07-14 | Kirin Beer Kabushiki Kaisha | Sphingoglycolipid compounds and therapeutic uses thereof |
| CN1125449A (zh) | 1993-05-14 | 1996-06-26 | 萨依特尔有限公司 | 作为细胞粘附抑制剂的唾液基Lex类似物 |
| EP1520583B1 (en) | 1997-04-10 | 2009-01-28 | Kyowa Hakko Kirin Co., Ltd. | NKT cell-activating agents containing alpha-glycosylceramides |
| EP1011719A1 (en) * | 1997-09-12 | 2000-06-28 | Brigham & Women's Hospital | Synthetic antigens for cd1-restricted immune responses |
| US20030153514A1 (en) | 2000-04-28 | 2003-08-14 | Akikuni Yagita | Remedies for cancer |
| US20020071842A1 (en) * | 2000-06-05 | 2002-06-13 | Gumperz Jenny E. | Soluble CD1 compositions and uses thereof |
| EP1297017B1 (en) * | 2000-06-19 | 2012-06-13 | Beth Israel Deaconess Medical Center | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| WO2001098317A2 (en) * | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| AU2002327338A1 (en) | 2001-07-25 | 2003-02-17 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| KR100549866B1 (ko) | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| CN1578667A (zh) | 2001-11-06 | 2005-02-09 | 东方癌症治疗株式会社 | 抗癌组合物 |
| WO2003105769A2 (en) * | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| WO2004094444A1 (en) | 2003-03-20 | 2004-11-04 | Brigham Young University | 6'-amino-6'-deoxygalactosylceramides |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| DK1786439T3 (da) | 2004-09-03 | 2010-07-12 | Univ Chicago | Fremgangsmåder til aktivering af NKT-celler |
| WO2007118234A2 (en) | 2006-04-07 | 2007-10-18 | The Scripps Research Institute | Modified -galactosyl ceramides for staining and stimulating natural killer t cells |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
-
2006
- 2006-01-26 DK DK06733921.8T patent/DK1848813T3/da active
- 2006-01-26 PL PL06733921T patent/PL1848813T3/pl unknown
- 2006-01-26 WO PCT/US2006/002781 patent/WO2006083671A2/en not_active Ceased
- 2006-01-26 ES ES06733921T patent/ES2423005T3/es not_active Expired - Lifetime
- 2006-01-26 AU AU2006211485A patent/AU2006211485B2/en not_active Ceased
- 2006-01-26 CA CA2593715A patent/CA2593715C/en not_active Expired - Fee Related
- 2006-01-26 BR BRPI0607299-2A patent/BRPI0607299A2/pt not_active IP Right Cessation
- 2006-01-26 EP EP06733921.8A patent/EP1848813B1/en not_active Expired - Lifetime
- 2006-01-26 JP JP2007553225A patent/JP5053101B2/ja not_active Expired - Fee Related
- 2006-01-26 PT PT67339218T patent/PT1848813E/pt unknown
- 2006-01-26 US US11/814,103 patent/US9295722B2/en not_active Expired - Fee Related
-
2007
- 2007-07-26 ZA ZA200706208A patent/ZA200706208B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1848813T3 (pl) | 2013-09-30 |
| WO2006083671A2 (en) | 2006-08-10 |
| US9295722B2 (en) | 2016-03-29 |
| BRPI0607299A2 (pt) | 2009-08-25 |
| JP5053101B2 (ja) | 2012-10-17 |
| EP1848813A2 (en) | 2007-10-31 |
| AU2006211485B2 (en) | 2011-04-14 |
| US20080279894A1 (en) | 2008-11-13 |
| JP2008528608A (ja) | 2008-07-31 |
| CA2593715C (en) | 2015-05-05 |
| AU2006211485A1 (en) | 2006-08-10 |
| PT1848813E (pt) | 2013-07-15 |
| ZA200706208B (en) | 2008-04-30 |
| EP1848813B1 (en) | 2013-04-10 |
| EP1848813A4 (en) | 2008-07-09 |
| ES2423005T3 (es) | 2013-09-17 |
| WO2006083671B1 (en) | 2007-04-12 |
| WO2006083671A3 (en) | 2007-02-22 |
| CA2593715A1 (en) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2178460A4 (en) | cartilage transplants | |
| PL2634242T3 (pl) | Ulepszony sposób hodowli komórek | |
| BRPI0816613A2 (pt) | novos derivados de oligossacarideos sulfatados | |
| EP2173353A4 (en) | Transplants | |
| BRPI0716881A2 (pt) | Composições tópicas | |
| BRPI0716762A2 (pt) | melhorias da cultura celular | |
| DE602006011777D1 (de) | Acrylhaftklebstoffzusammensetzung für polarisationsfolie | |
| CR9902A (es) | Drrivados de amida heterociclica utiles como microbiocidas | |
| EP1958592A4 (en) | intraocular lens | |
| DK1913135T3 (da) | Extracellulære polyhydroxyalkanoater frembragt af genetisk modificerede mikroorganismer | |
| DK2139936T3 (da) | Polyurethansammensætning indeholdende asymmetrisk dialdimin | |
| EP2245546A4 (en) | ASYNCHRONOUS REPLICATION | |
| EP2083933A4 (en) | IMPROVED MEMBRANE MODULE | |
| EP1848813A4 (en) | ACTIVATION OF BACTERIAL GLYCOLIPID OF CD1D-LIMITED NKT CELLS | |
| DK2027150T3 (da) | Allo-begrænsede peptid-specifikke t-celler | |
| DE602007008627D1 (de) | Zellkulturmedium | |
| BRPI0814572A2 (pt) | Célula de lítio | |
| BRPI0813726A2 (pt) | Célula de lítio | |
| EP1937307A4 (en) | SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS | |
| DK1838295T3 (da) | Anthelmintisk sammensætning | |
| DE602006004859D1 (de) | Flüssigkristallines polymer enthaltende zusammensetzung | |
| FR2917971B1 (fr) | Composition amincissante | |
| DE502008000917D1 (de) | Lautsprecherbox | |
| SI1848813T1 (sl) | Aktiviranje bakterijskega glikopida s CD1D omenjenih NKT-celic | |
| EP1942946A4 (en) | BIOLOGICALLY AVAILABLE CELLS |